Ulrik Lassen

Department of Oncology, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen

Disclosure: Nothing to disclose

Presentation(s):

• PATH-28 - Angiotensinogen promoter methylation to predict bevacizumab response in recurrent glioblastoma patients

  Friday, November 22
  7:30 PM – 9:30 PM

• EPID-13 - Identification of prognostic markers in a cohort of consecutive non-selected glioblastoma patients receiving standard therapy

  Saturday, November 23
  5:00 PM – 7:00 PM

• ATIM-01 - Nivolumab and bevacizumab for recurrent glioblastoma; a translational trial in progress

  Saturday, November 23
  5:00 PM – 7:00 PM